Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer

A technology of ovarian cancer and composition, applied in the field of breast cancer/ovarian cancer prevention, can solve problems such as high toxicity

Inactive Publication Date: 2006-09-20
POMERANIAN ACAD OF MEDICINE +10
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While these forms have some value, they are more toxic than needed and not particularly effective in cancer chemoprevention"

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Selenium-containing composition

[0024] Based on the information obtained from pharmacopoeias, the skilled person can prepare different variants of compositions containing selenium, especially selenium (quaternary). For example, it can be obtained from organic forms such as methylcysteine, methylselenate, selenomethionine, selenocysteine ​​or from organic forms such as selenium dioxide, selenate, H 2 SeO 3 Selenium is selected as the inorganic form of its salts. For example, a more valuable selenium (quaternary) salt for preparing compositions according to the invention is sodium selenite. Natural products with higher concentrations of selenium, such as selenium-enriched yeast or cauliflower are also very interesting compounds.

[0025] Of particular value, although not exclusively, the composition of the invention is a solution, especially an isotonic solution, having a selenium concentration of 0.1-10% by weight. Such solutions can be prepared, for exam...

Embodiment 2

[0032] Example 2 Oral selenium supplementation reduces the higher rate of chromosome breakage in BRCA1 carriers

[0033] Test subjects were recruited from patients attending the Single Family Cancer Clinic of the Center for Genetic Cancers of the Pomeranian Medical Research Institute in Szczecin, Poland. Women are more likely to come to this clinic because of their family history of breast or ovarian cancer. The women participating in this study had previously undergone, or had consented to, genetic testing. Female patients were recruited from carriers identified as having a deletion mutation in the BRCA1 gene. The most common mutation was the Polish founder mutation with a C insertion at position 5382 (16 carriers), and 10 women had other BRCA1 mutations. Control individuals were recruited from family members of these carriers (patients) and determined not to carry the deletion mutation. 26 patient-control pairs were obtained. In 20 cases the control was the patient's sis...

Embodiment 3

[0040] Example 3 Supplementing selenium for female BRCA1 mutation carriers can significantly reduce the susceptibility to breast / ovarian cancer

[0041] We conducted a 2-year study on 30 initially healthy BRCA1 mutation carriers who took 300 μg sodium selenite ethanol solution orally every day, and a control group of 30 BRCA1 carriers whose mutation type matched the birth year, and observed breast cancer / ovarian cancer incidence rate. The average age of the two groups was 46.5 years. During the observation period, 1 case of breast cancer was diagnosed in the selenium supplementation group, while 4 cases of breast cancer and 1 case of ovarian cancer were diagnosed in the control group. (table 3)

[0042] In addition, the incidence of de novo breast / ovarian cancer in the experimental group supplemented with sodium selenite ethanol solution at a dose of 300 μg / day and the control group were analyzed for 1 year. The experimental group consisted of 200 initially unaffected The c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns pharmaceutical composition of selenium (or its salts or derivatives or any other selenium comprising compound) and a method of its use for the prevention of breast / ovarian cancers, especially in carriers of BRCA1 mutations. Preferred compounds are selenic acid and its salt, selenomethylcysteine, methylseleninic acid, selenomethionine and selenocysteine.

Description

field of invention [0001] The present invention relates to compositions of selenium (or its salts or derivatives thereof or any other selenium compounds) and methods for preventing breast / ovarian cancer in women with hereditary high susceptibility to cancer, especially in carriers of BRCA1 gene mutation . Background of the invention [0002] The BRCA1 (US Patent No. 5654155) and BRCA2 genes are associated with a high genetic predisposition for cancer. The BRCA1 and BRCA2 genes have been cloned, and abnormalities can now be detected at the DNA and RNA levels. Carriers of the above gene mutations have a higher susceptibility to breast and / or ovarian cancer. BRCA1 is the first gene known to be associated with high susceptibility to breast and ovarian cancer (Miki et al, Science, 266-271, 1994). BRCA1 (GENBANK accession numbers: U14680 and 15595) contains 24 exons interspersed within 100 kb of genomic DNA, and its mRNA is 7.8 kb in length. Intensive studies of this gene have...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/095A61K31/198A61K33/04A61P35/00
CPCA61K31/198A61K33/04A61K31/095A61P35/00
Inventor 杨·卢宾斯基史蒂文·纳罗德斯坦尼斯瓦夫·扎亚茨亚克埃尔兹比尔塔·科瓦尔斯卡博赫丹·古尔斯基托马什·胡扎斯基托马什·比尔斯基亚采克·格龙瓦尔德乔伊塔·胡扎斯卡芭芭拉·加夫龙斯卡-什克拉尔兹
Owner POMERANIAN ACAD OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com